Proteomic Analysis in Paediatric Diabetes Type 1 (PAPD)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-10
SponsorAristotle University Of Thessaloniki

About this trial

The aim of the present study is to investigate a targeted proteomic analysis in plasma of children - of Greek origin- with type 1 diabetes (DT1) and its correlation with the electrophysiological findings that accompany diabetic peripheral neuropathy.

Diabetic neuropathy is the most frequent chronic complication in adults with DT1 and rarely appears in childhood. Nevertheless, cases of acute mononeuritis have been described at the time of diagnosis of DT1. According to recent reports several biomarkers, including proteomic analysis, have been proposed for the early detection of peripheral neuropathy in children and young adults with T1DM.

In the present study the researchers will attempt to investigate the role of biomarkers with targeted proteomic analysis in the plasma of children with DT1 in combination with an electrophysiological study, which includes a nerve conduction study, to detect early diabetic peripheral neuropathy, before the appearance of clinical manifestations.

Eligibility criteria

Qualifiers

Children with confirmed DT1 under insulin substitution therapy

Age 5-10 years

Good glycemic control with HbA1c ≤ 7.0%

Prepubertal patients

Disqualifiers

Presence of organic cause for neuropathy

Presence of other chronic disease

Poor glycemic control

Trial design

Treatments tested in this trial

  • Blood sampling

Treatment groups

50 Participants
are divided into 2 treatment groups